Résumé
We welcome the contribution by Taramasso et al. to stopping rules for weight gain in clinical trials. Our original recommendation, to offer a voluntary switch to efavirenz in those on dolutegravir with the highest BMI gains, was made in the light of available evidence, and specifically in relation to continuation of patients enrolled into ADVANCE. Since then, new evidence has emerged to suggest that patients with highest exposures to efavirenz may gain less weight because of drug toxicity [...].